Is anyone looking into $MLTX after that post that one person did, I’d love to get a hit on a biotech squeeze

---

Look what happened to Martin shkreli’s professional DD on $CAPR, no one really knows shit lol. I’m doing lotto puts on MLTX for the gambol. 100 cons $10p

---

They have a drug that looks to be effective against a wide spectrum of chronic inflammatory diseases. It fell from 60 because the headlines say the drug failed and is not effective. Data shows efficacy and I expect the FDA will give them a pathway to SLK approval next week. MLTX isn’t selling out they have the cash to commercialization, SLK is going to be a CID blockbuster. HS and PPP are just the start, management is going to roll down the line and get this approved for a wide variety of indications.

---